|1.||Sabo, John P: 2 articles (03/2011 - 12/2005)|
|2.||Tomillero, A: 2 articles (12/2010 - 05/2009)|
|3.||Moral, M A: 2 articles (12/2010 - 05/2009)|
|4.||Anta, Lourdes: 2 articles (07/2010 - 10/2009)|
|5.||Soriano, Vincent: 2 articles (07/2010 - 10/2009)|
|6.||Rusconi, Stefano: 2 articles (07/2009 - 03/2004)|
|7.||Temesgen, Zelalem: 2 articles (09/2007 - 11/2005)|
|8.||De Clercq, E: 2 articles (01/2007 - 04/2002)|
|9.||Mauss, Stefan: 1 article (03/2011)|
|10.||MacGregor, Thomas R: 1 article (03/2011)|
|1.||HIV Infections (HIV Infection)
02/01/2009 - "[Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection]."
01/01/2008 - "Tipranavir: a review of its use in the management of HIV infection."
09/15/2007 - "Tipranavir: a new option for the treatment of drug-resistant HIV infection."
05/01/2010 - "Tipranavir (TPV) is the first nonpeptidic protease inhibitor used for the treatment of drug-resistant HIV infection. "
05/01/2007 - "Tipranavir, a nonpeptidic HIV-1 protease inhibitor, has been recently approved for the treatment of HIV infection. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
10/01/2009 - "Three genotypic inhibitory quotients (gIQs) were calculated by using different TPV resistance mutation scores (from the International AIDS Society-USA [IAS-USA], Randomized Evaluation of Strategic Intervention in Multidrug-Resistant Patients with Tipranavir [RESIST], and Agence Nationale de Recherches sur le Sida et les Hépatites Virales [ANRS] trials). "
06/01/2008 - "The tipranavir response by FIV may 1) support the idea of using FIV as a small animal model for PI-resistant HIV-1, thus expanding access to animal AIDS models; and 2) pave the way for development of novel broad-based inhibitors for treatment of drug resistant HIV-1."
07/01/2010 - "The presence of resistance mutations in patients failing tipranavir or darunavir was examined at the national drug resistance database of the Spanish AIDS Research Network. "
07/01/2009 - "Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resistant strains, can be used in salvage therapies for multi-experienced HIV patients due to its peculiar resistance profile including 21 mutations at 16 protease positions according to International AIDS Society (IAS). "
01/01/2008 - "The results suggest that the two inhibitors nelfinavir and tipranavir could be used for treatment of AIDS by targeting the enzyme HIV protease as neither of the two inhibitors exhibit any cross-reactivity with other human proteins, they readily bind to the mutated enzyme active site and still remain linked with the enzyme-substrate complex in the presence of water molecules. "
06/01/2007 - "For other drugs such as antiarrhythmics, antihistamines, ergot derivatives, selective serotonin receptor agonists (or triptans), gastrointestinal motility agents, erectile dysfunction agents, and calcium channel blockers, interactions can be predicted based on studies with other ritonavir-boosted protease inhibitors and what is known about tipranavir-ritonavir CYP and P-glycoprotein utilization. "
11/01/2008 - "Tipranavir-resistance associated mutations (TPV-RAMs) are often observed among patients with HIV-1 subtype A/E infection. "
11/01/2008 - "Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection."
01/01/2008 - "Thus, tipranavir, administered with ritonavir, is an effective treatment option for use in the combination therapy of adults with HIV-1 infection who have been previously treated with other antiretroviral drugs."
01/01/2008 - "In treatment-experienced adults with HIV-1 infection receiving an optimized background regimen, viral suppression was greater and immunological responses were better with regimens containing tipranavir/ritonavir than with comparator ritonavir-boosted PI-containing regimens. "
03/01/2004 - "Our in vitro experiments did not show any advantage in combining second generation PIs as a therapeutic strategy in naive or multi-treatment failure subjects, with the exception of tipranavir + amprenavir at IC(95) in infections by a wild-type isolate."
|1.||Protease Inhibitors (Protease Inhibitor)
|4.||Serotonin Receptor Agonists (Serotonin Receptor Agonist)
|6.||Histamine Antagonists (Antihistamines)
|7.||Calcium Channel Blockers (Blockers, Calcium Channel)
|2.||Highly Active Antiretroviral Therapy (HAART)